Immunic, Inc. Regains Nasdaq Compliance and Provides Development Update
Immunic, Inc. Regains Nasdaq Compliance and Provides Development Update
Key Highlights
- Immunic, Inc. (Nasdaq: IMUX) has regained compliance with the Nasdaq minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.
- The company’s stock price closed at or above \$1.00 for at least 20 consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2).
- Immunic’s lead asset, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026.
- The company’s pipeline also includes IMU-856 and IMU-381, targeting neurodegenerative, chronic inflammatory, and autoimmune diseases.
- Immunic has issued a forward-looking statement highlighting both opportunities and substantial risks, including macroeconomic uncertainties, the need for continued capital, and the unpredictable nature of clinical development.
Details for Investors
Immunic, Inc., a late-stage biotechnology company focused on developing novel oral therapies for neurological diseases, has announced a significant regulatory milestone. On March 27, 2026, the company received written confirmation from Nasdaq’s Listing Qualifications Department stating that Immunic has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The compliance was achieved after the company’s common stock maintained a closing bid price of at least \$1.00 for 20 consecutive business days, with the requirement met as of March 26, 2026. This closes a potentially risky chapter for shareholders, as non-compliance could have resulted in delisting and significant negative pressure on the share price.
Potential Price-Sensitive Developments
- Nasdaq Compliance Restored: Compliance with minimum bid price is a critical listing requirement. Regaining it removes the immediate risk of delisting and may restore investor and market confidence, potentially providing upward momentum for the share price.
- Lead Program Advancement: Immunic’s primary asset, vidofludimus calcium (IMU-838), is currently undergoing phase 3 clinical trials for relapsing multiple sclerosis. The company expects to report top-line data by the end of 2026. If successful, these results could be highly price-sensitive, with significant implications for the company’s valuation and market potential.
- Therapeutic Potential and Differentiation: Vidofludimus calcium has demonstrated therapeutic activity in earlier phase 2 studies for both relapsing-remitting and progressive multiple sclerosis, as well as other diseases. The drug uniquely combines neuroprotective action (as a first-in-class Nurr1 activator) with anti-inflammatory and anti-viral effects (via selective DHODH inhibition).
- Broader Pipeline: Beyond its lead candidate, Immunic is developing additional assets—IMU-856 and IMU-381—aimed at addressing a range of neurodegenerative, chronic inflammatory, and autoimmune conditions.
Risks and Cautions for Shareholders
- Immunic’s forward-looking statements emphasize substantial risks, including macroeconomic volatility (inflation, tariffs, and global conflicts), the unpredictable nature of clinical development, and the company’s ongoing need to raise capital to sustain operations.
- The company warns that earlier preclinical and clinical results may not be predictive of future outcomes. Changes in target market size, competition, intellectual property protection, and the regulatory environment could all materially impact future performance.
- Shareholders should closely monitor Immunic’s cash position, operational runway, and progress of clinical trials, as these will be key determinants of future value and share price movements.
Contact Information
Investor Relations: Jessica Breu, Vice President IR & Communications, +49 89 2080 477 09, [email protected]
US IR Contact: Paula Schwartz, Rx Communications Group, +1 917 633 7790, [email protected]
Media Contact: Caitlin Kasunich, KCSA Strategic Communications, +1 212 896 1241, [email protected]
Additional Resources
Disclaimer: This article contains forward-looking statements that are subject to substantial risks and uncertainties. Actual results may differ materially from those projected. Investors should not rely solely on this article for investment decisions and are encouraged to review official filings and consult with financial advisors. Immunic, Inc. expressly disclaims any intent or obligation to update these forward-looking statements based on subsequent developments.
View IMMUNIC, INC. Historical chart here
